Loading...

Synlogic

Nasdaq:SYBX
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SYBX
Nasdaq
$210M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
SYBX Share Price and Events
7 Day Returns
0%
NasdaqGM:SYBX
-5.7%
US Biotechs
-3.9%
US Market
1 Year Returns
-17.2%
NasdaqGM:SYBX
-7.9%
US Biotechs
1.4%
US Market
SYBX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Synlogic (SYBX) 0% -0.4% -11.1% -17.2% - -
US Biotechs -5.7% -8.7% -6.4% -7.9% 5.5% 10.5%
US Market -3.9% -3.6% 1.8% 1.4% 35.8% 40.8%
1 Year Return vs Industry and Market
  • SYBX underperformed the Biotechs industry which returned -7.9% over the past year.
  • SYBX underperformed the Market in United States of America which returned 1.4% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

SYBX Value

 Is Synlogic undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Synlogic. This is due to cash flow or dividend data being unavailable. The share price is $8.26.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Synlogic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Synlogic's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SYBX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.00
NasdaqGM:SYBX Share Price ** NasdaqGM (2019-05-15) in USD $8.26
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.35x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Synlogic.

NasdaqGM:SYBX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SYBX Share Price ÷ EPS (both in USD)

= 8.26 ÷ -2.00

-4.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synlogic is loss making, we can't compare its value to the US Biotechs industry average.
  • Synlogic is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Synlogic's expected growth come at a high price?
Raw Data
NasdaqGM:SYBX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.14x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.15x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Synlogic, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Synlogic's assets?
Raw Data
NasdaqGM:SYBX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.42
NasdaqGM:SYBX Share Price * NasdaqGM (2019-05-15) in USD $8.26
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.11x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGM:SYBX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SYBX Share Price ÷ Book Value per Share (both in USD)

= 8.26 ÷ 4.42

1.87x

* Primary Listing of Synlogic.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synlogic is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Synlogic's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Synlogic has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SYBX Future Performance

 How is Synlogic expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Synlogic expected to grow at an attractive rate?
  • Unable to compare Synlogic's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Synlogic's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Synlogic's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SYBX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SYBX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 8%
NasdaqGM:SYBX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 98.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SYBX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SYBX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 133 -24 -10 5
2022-12-31 14 -79 -94 5
2021-12-31 0 -76 -91 6
2020-12-31 2 -54 -75 5
2019-12-31 2 -56 -60 5
NasdaqGM:SYBX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 3 -43 -50
2018-12-31 3 -42 -48
2018-09-30 3 -43 -48
2018-06-30 1 -40 -49
2018-03-31 3 -37 -44
2017-12-31 2 -31 -40
2017-09-30 2 -29 -36
2017-06-30 2 -26 -29
2017-03-31 0 -23 -24
2016-12-31 0 -20 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Synlogic is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Synlogic's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SYBX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Synlogic Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SYBX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.07 1.23 -1.25 5.00
2022-12-31 -2.31 -1.27 -2.82 5.00
2021-12-31 -2.49 -1.72 -3.24 6.00
2020-12-31 -2.49 -1.91 -2.93 8.00
2019-12-31 -2.27 -1.93 -2.65 8.00
NasdaqGM:SYBX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.00
2018-12-31 -2.03
2018-09-30 -2.24
2018-06-30 -2.89
2018-03-31 -3.89
2017-12-31 -6.00
2017-09-30 -11.27
2017-06-30 -26.51
2017-03-31 -18.86
2016-12-31 -13.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Synlogic will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Synlogic's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Synlogic has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SYBX Past Performance

  How has Synlogic performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Synlogic's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Synlogic does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Synlogic's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Synlogic's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Synlogic's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Synlogic Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SYBX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2.50 -50.22 14.94 40.06
2018-12-31 2.52 -48.44 14.92 38.03
2018-09-30 2.52 -48.20 15.36 36.90
2018-06-30 0.83 -49.38 15.89 35.92
2018-03-31 2.69 -44.17 14.19 33.58
2017-12-31 2.44 -40.38 12.93 30.34
2017-09-30 2.44 -35.53 10.48 27.73
2017-06-30 2.44 -28.91 8.53 22.91
2017-03-31 0.44 -24.49 7.15 17.80
2016-12-31 0.44 -20.95 6.40 15.01
2015-12-31 -8.53 4.50 4.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Synlogic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Synlogic has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Synlogic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Synlogic's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Synlogic has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SYBX Health

 How is Synlogic's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Synlogic's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Synlogic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Synlogic's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Synlogic's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Synlogic Company Filings, last reported 1 month ago.

NasdaqGM:SYBX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 112.21 24.10 109.84
2018-12-31 124.10 0.48 122.73
2018-09-30 135.03 0.57 132.62
2018-06-30 144.62 0.69 143.21
2018-03-31 128.77 0.78 125.80
2017-12-31 85.04 0.89 87.03
2017-09-30 95.57 0.43 96.57
2017-06-30 66.38 0.27 66.83
2017-03-31 32.91 0.32 34.15
2016-12-31 13.50 0.38 14.59
2015-12-31 3.36 0.09 6.18
  • Synlogic's level of debt (21.5%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Synlogic's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Synlogic has sufficient cash runway for 2.4 years based on current free cash flow.
  • Synlogic has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 35.8% each year.
X
Financial health checks
We assess Synlogic's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Synlogic has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SYBX Dividends

 What is Synlogic's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Synlogic dividends. Estimated to be 0% next year.
If you bought $2,000 of Synlogic shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Synlogic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Synlogic's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SYBX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SYBX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Synlogic has not reported any payouts.
  • Unable to verify if Synlogic's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Synlogic's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Synlogic has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Synlogic's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Synlogic's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Synlogic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Synlogic has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SYBX Management

 What is the CEO of Synlogic's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Aoife Brennan
AGE 42
TENURE AS CEO 1 years
CEO Bio

Dr. Aoife M. Brennan, M.D. M.B., B.Ch. has been a Director at Ra Pharmaceuticals, Inc since September 21, 2018. Dr. Brennan serves Chief Medical Officer of Synlogic, Inc. since September 12, 2016 and had served as its Interim President & CEO from May 2018 to October 2, 2018. She has been the President, Chief Executive Officer & Director of Synlogic Inc. since October 2, 2018. Dr. Brennan is responsible for the oversight and direction of the Synlogic's clinical development strategy and operations. Dr. Brennan joined Synlogic following six years at Biogen, where she was in roles of increasing responsibility and served as vice president and head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. She has also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX and ELOCTATE, treatments for Hemophilia B and Hemophilia A. She served as Senior Medical Director of Clinical Development at Biogen Inc. (alternate name, Biogen Idec Inc.). Prior to joining Biogen, Dr. Brennan was Director of Clinical Development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. Prior to joining the biotechnology industry, she was a Clinical Research Fellow in the Division of Endocrinology, Diabetes, and Metabolism at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center in Boston,

CEO Compensation
  • Aoife's compensation has increased whilst company is loss making.
  • Insufficient data for Aoife to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Synlogic management team in years:

1
Average Tenure
53
Average Age
  • The average tenure for the Synlogic management team is less than 2 years, this suggests a new team.
Management Team

Peter Barrett

TITLE
Executive Chairman
COMPENSATION
$154K
AGE
65
TENURE
1 yrs

JC Gutierrez-Ramos

TITLE
COMPENSATION
$2M
AGE
55

Aoife Brennan

TITLE
President
AGE
42
TENURE
1 yrs

Tim Lu

TITLE
Co-Founder

Jim Collins

TITLE
Co-Founder

Todd Shegog

TITLE
Chief Financial Officer
AGE
53
TENURE
2.7 yrs

Tony Awad

TITLE
Head of Technical Operations
TENURE
0.4 yrs

Scott Plevy

TITLE
Chief Scientific Officer
TENURE
0.1 yrs

Liz Wolffe

TITLE
Head of Investor Relations & Corporate Communications

Maiken Keson-Brookes

TITLE
General Counsel
AGE
45
Board of Directors Tenure

Average tenure and age of the Synlogic board of directors in years:

3.2
Average Tenure
58
Average Age
  • The tenure for the Synlogic board of directors is about average.
Board of Directors

Aoife Brennan

TITLE
President
AGE
42

Ed Mathers

TITLE
Director
COMPENSATION
$174K
AGE
58
TENURE
6.6 yrs

Peter Barrett

TITLE
Executive Chairman
COMPENSATION
$154K
AGE
65
TENURE
2.2 yrs

Mike Powell

TITLE
Director
COMPENSATION
$190K
AGE
63
TENURE
6.6 yrs

Rick Shea

TITLE
Director
COMPENSATION
$146K
AGE
66
TENURE
1.8 yrs

Chau Khuong

TITLE
Director
COMPENSATION
$144K
AGE
42
TENURE
3.3 yrs

Paul Miller

TITLE
Member Scientific Advisory Board
COMPENSATION
$437K
AGE
58

Charlotte Hubbert

TITLE
Observer

Nick Leschly

TITLE
Independent Director
COMPENSATION
$315K
AGE
45
TENURE
3.2 yrs

Patricia Hurter

TITLE
Independent Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Synlogic's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Synlogic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SYBX News

Simply Wall St News

Imagine Owning Synlogic And Wondering If The 19% Share Price Slide Is Justified

But that is minimal compensation for the share price under-performance over the last year. … After all, the share price is down 19% in the last year, significantly under-performing the market. … With the share price down 19% in the last year, it seems likely that the need for cash is weighing on investors' minds.

Simply Wall St -

How Much Of Synlogic Inc (NASDAQ:SYBX) Do Institutions Own?

Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … We can zoom in on the different ownership groups, to learn more about SYBX

Simply Wall St -

Should You Be Concerned About Synlogic Inc's (NASDAQ:SYBX) Investors?

Today, I will be analyzing Synlogic Inc’s (NASDAQ:SYBX) recent ownership structure, an important but not-so-popular subject among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Therefore, it is beneficial for us to examine SYBX's ownership structure in more detail.

Simply Wall St -

Brokers' Outlook On Synlogic Inc (NASDAQ:SYBX)

SYBX has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like SYBX as a business is its low level of fixed assets on its balance sheet (9.61% of total assets). … SYBX has virtually no fixed assets, which minimizes its downside risk.

Simply Wall St -

Why Synlogic Inc (SYBX) Has Zero-Debt On Its Balance Sheet

Synlogic Inc (NASDAQ:SYBX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … See our latest analysis for SYBX Does SYBX's growth rate justify its decision for financial flexibility over lower cost of capital? … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

SYBX Company Info

Description

Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Details
Name: Synlogic, Inc.
SYBX
Exchange: NasdaqGM
Founded:
$209,710,191
25,388,643
Website: http://www.synlogictx.com
Address: Synlogic, Inc.
301 Binney Street,
Suite 402,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SYBX Common Shares Nasdaq Global Market US USD 28. Aug 2017
DB MINA Common Shares Deutsche Boerse AG DE EUR 28. Aug 2017
Number of employees
Current staff
Staff numbers
74
Synlogic employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 02:52
End of day share price update: 2019/05/15 00:00
Last estimates confirmation: 2019/05/14
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.